Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals

For two decades, PCSK9 inhibition required monoclonal antibodies delivered by injection—until now. Merck’s enlicitide represents a medicinal chemistry triumph, demonstrating that a once-daily small molecule can achieve comparable LDL lowering without cold chain or needle logistics, potentially accelerating the drug’s adoption in a class that has struggled to meet commercial expectations.

The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, marking a significant evolution in the management of high cholesterol. Announced by Merck on July 16, 2026, this approval provides a new treatment avenue for millions of adults with hypercholesterolemia, including those with inherited forms, for whom existing lipid-lowering therapies may be insufficient. The drug works by blocking the PCSK9 protein, enhancing the liver's ability to clear LDL cholesterol, and is taken as a tablet alongside diet and other cholesterol-lowering medications.

“

Until now, the PCSK9 inhibitor class—represented by Repatha (Amgen) and Praluent (Sanofi/Regeneron)—has been available only as injectable monoclonal antibodies.

Until now, the PCSK9 inhibitor class—represented by Repatha (Amgen) and Praluent (Sanofi/Regeneron)—has been available only as injectable monoclonal antibodies. Despite their potent LDL-lowering effects, uptake was hampered by needle aversion, administration in physician offices, and high costs often exceeding $600 per month. Lipfendra’s oral formulation directly addresses these barriers, potentially expanding the addressable market dramatically. In the pivotal Phase 3 CORALreef trials, Lipfendra demonstrated LDL-C reductions of 56% (CORALreef Lipids) and 59% (CORALreef HeFH) compared to placebo over 24 weeks. This is roughly double the efficacy of high-intensity statin monotherapy and comparable to injectable PCSK9 inhibitors, but without the need for injections.

The approval carries both clinical and commercial implications. At a list price of $315 per month, Merck is pricing Lipfendra at roughly half the cost of existing PCSK9 therapies, a strategic move that could accelerate adoption while pressuring competitors. However, the drug’s strict fasting requirement—patients must abstain from food for eight hours before each dose—could be a hurdle for real-world adherence, even as studies suggest that pill-based therapies generally see better compliance than injectables. Common side effects included diarrhea and dizziness, with overall discontinuation rates similar to placebo, indicating a favorable safety profile.

The FDA reviewed the drug under its National Priority Voucher program, which aims to incentivize treatments addressing significant public health needs. Cardioavascular disease remains the leading cause of death globally, and elevated LDL cholesterol is a major modifiable risk factor. Statins, while effective and inexpensive, leave many patients short of LDL targets, particularly those with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease. The introduction of an oral PCSK9 inhibitor could reshape treatment guidelines and shift the standard of care toward earlier and more aggressive LDL lowering.